Lilly Endowment Inc Sells 6,181 Shares of Eli Lilly and Company (NYSE:LLY) Stock

Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 6,181 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $555.32, for a total transaction of $3,432,432.92. Following the sale, the insider now owns 100,240,351 shares in the company, valued at $55,665,471,717.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

• On Monday, August 28th, Lilly Endowment Inc sold 37,660 shares of Eli Lilly and Company stock. The stock was sold at an average price of $546,751.75, for a total transaction of $20,590,670,905.00.
• On Friday, August 25th, Lilly Endowment Inc sold 63,572 shares of Eli Lilly and Company stock. The stock was sold at an average price of $554.38, for a total transaction of $35,243,045.36.
• On Wednesday, August 23rd, Lilly Endowment Inc sold 1,307 shares of Eli Lilly and Company stock. The stock was sold at an average price of $555.69, for a total transaction of $726,286.83.
• On Monday, August 14th, Lilly Endowment Inc sold 164,778 shares of Eli Lilly and Company stock. The stock was sold at an average price of $539.08, for a total transaction of $88,828,524.24.
• On Thursday, August 10th, Lilly Endowment Inc sold 3,000 shares of Eli Lilly and Company stock. The shares were sold at an average price of $528.13, for a total transaction of $1,584,390.00.
• On Tuesday, August 8th, Lilly Endowment Inc sold 204,409 shares of Eli Lilly and Company stock. The shares were sold at an average price of $523.74, for a total transaction of $107,057,169.66.
• On Friday, July 21st, Lilly Endowment Inc sold 591 shares of Eli Lilly and Company stock. The shares were sold at an average price of $466.62, for a total transaction of $275,772.42.
• On Friday, June 30th, Lilly Endowment Inc sold 164,125 shares of Eli Lilly and Company stock. The shares were sold at an average price of $467.60, for a total transaction of $76,744,850.00.
• On Wednesday, June 28th, Lilly Endowment Inc sold 11,760 shares of Eli Lilly and Company stock. The shares were sold at an average price of $465.41, for a total transaction of $5,473,221.60.
• On Thursday, June 22nd, Lilly Endowment Inc sold 107,022 shares of Eli Lilly and Company stock. The shares were sold at an average price of $459.28, for a total transaction of $49,153,064.16.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $557.11 on Friday. The company has a market cap of $528.86 billion, a PE ratio of 77.48, a price-to-earnings-growth ratio of 2.28 and a beta of 0.35. Eli Lilly and Company has a 12 month low of $296.32 and a 12 month high of $559.21. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87. The company has a 50-day simple moving average of $488.90 and a 200-day simple moving average of $420.11.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The firm had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $7.58 billion. During the same period in the previous year, the firm earned $1.25 earnings per share. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post 9.83 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 14th. This represents a $4.52 dividend on an annualized basis and a yield of 0.81%. Eli Lilly and Company’s payout ratio is 62.87%.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently bought and sold shares of the stock. Silicon Valley Capital Partners purchased a new stake in Eli Lilly and Company in the first quarter valued at approximately $25,000. Retirement Group LLC grew its stake in Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after buying an additional 35 shares during the period. Bogart Wealth LLC grew its stake in Eli Lilly and Company by 193.3% during the first quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after buying an additional 58 shares during the period. Laffer Tengler Investments purchased a new stake in Eli Lilly and Company during the first quarter worth approximately $33,000. Finally, Cornerstone Planning Group LLC purchased a new stake in Eli Lilly and Company during the second quarter worth approximately $33,000. 81.38% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently commented on LLY shares. Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $560.00 to $617.00 and gave the company an “overweight” rating in a research note on Wednesday, August 9th. 22nd Century Group reiterated a “maintains” rating on shares of Eli Lilly and Company in a research note on Tuesday, June 27th. Truist Financial raised their price objective on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. Bank of America raised their price objective on shares of Eli Lilly and Company from $500.00 to $600.00 in a research note on Wednesday, August 9th. Finally, UBS Group raised their price objective on shares of Eli Lilly and Company from $447.00 to $498.00 and gave the company a “buy” rating in a research note on Wednesday, May 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $520.48.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.